BRIXADI 64 mg/.18mL
BUPRENORPHINE · INJECTION · Braeburn Inc.
No Recall History
Plain English
BRIXADI is a injection containing buprenorphine at 64 mg/.18mL, taken subcutaneous. Manufactured by Braeburn Inc..
Key Facts
- Brand Name
- BRIXADI
- Generic Name
- BUPRENORPHINE
- NDC Code (Product)
58284-264- Manufacturer
- Braeburn Inc.
- Strength
- 64 mg/.18mL
- Dosage Form
- INJECTION
- Route
- SUBCUTANEOUS
- Marketing Status
- DEA Schedule
- Schedule III (Controlled)
- Application #
- NDA210136
- Drug Class
- Partial Opioid Agonist [EPC]
- Marketing Start
- 06/06/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is BRIXADI used for?
BRIXADI contains BUPRENORPHINE. It is a injection taken subcutaneous. Consult your doctor for specific uses.
Is BRIXADI a controlled substance?
Yes, BRIXADI is classified as CIII under the DEA Controlled Substances Act.
What is the generic name for BRIXADI?
The generic name for BRIXADI is BUPRENORPHINE. There are 12 other brand versions of BUPRENORPHINE.
What is the NDC code for BRIXADI 64 mg/.18mL?
The NDC (National Drug Code) for BRIXADI 64 mg/.18mL is 58284-264, listed by Braeburn Inc..
Other Buprenorphine Brands
See all →- Buprenorphine and Naloxone2 mg/172162-1346
- Buprenorphine8 mg/10904-7155
- Suboxone8 mg/112496-1208
- Buprenorphine7.5 ug/h0093-3239
- Buprenorphine and Naloxone8 mg/131722-481
- Buprenorphine20 ug/h3215-1525
- BUPRENORPHINE8 mg/142858-502
- Buprenorphine5 ug/h42858-750
- buprenorphine transdermal system10 ug/h47781-407
- BUPRENORPHINE8 mg/150090-5805
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)